



## Meda acquires Aldara follow-up product from 3M

Meda has acquired the European rights to sotirimod from 3M. Sotirimod primary use is to treat actinic keratosis and is a follow-up to Aldara (active substance: imiquimod). Sotirimod and imiquimod are immunomodulatory drugs that activate the body's own immune defences through the skin, which help to fight skin lesions such as actinic keratosis. Aldara is the market leader within its segment with annual sales of SEK 250 million and solid growth.

Sotirimod is a patented substance in late clinical development. It is more potent than imiquimod and has in study in humans been shown to treat actinic keratosis with higher efficacy than Aldara. Actinic keratosis is characterised by reddish-brown flaking on sunburned skin and can be precancerous. This disease affects more than 30 million people in Europe.

Meda paid USD 10 million for the product and may pay an additional USD 10 million in milestone payments at defined stages of development and commercialisation.

"Actinic keratosis is a common skin disease, so it's important to continue developing new, improved therapies in this area," says Anders Lönner, Meda's CEO. "Our goal is to develop sotirimod into a next generation Aldara that is more effective and easier to use. By acquiring sotirimod, Meda further expands its dermatology product portfolio."

For more information, please contact:

Anders Lönner, CEO, +46 8 630 19 00

Anders Larnholt, Investor Relations, +46 8 630 19 62, +46 709 458 878

---

**MEDA AB (publ)** is a leading European specialty pharma company that concentrates on marketing and market-adapted product development. Acquisitions and long-term partnerships are fundamental factors that drive the company's strategy. Meda is represented in more than 24 countries and has over 1000 employees within marketing and sales. The Meda share is quoted on the OMX Nordic Stock Exchange. To find out more, visit [www.meda.se](http://www.meda.se).